Jeffrey V. Ravetch

TL;DR: Assessment of the in-vivo activity of several broadly neutralizing antibodies against HIV-1 revealed that FcγR-mediated effector function contributes substantially to their capacity to block viral entry, suppress viremia, and confer therapeutic activity.

TL;DR: It is shown that inactivated RSV vaccines may be rendered safe and effective by inclusion of TLR agonists in their formulation, and affinity maturation is identified as a key factor for the safe immunization of infants.

TL;DR: The results lead to the surprising conclusion that these two systems have evolved distinct functions in host immunity, with complement and its receptors mediating the interaction of natural antibodies with pathogens to effect protection, while FcRs coupleThe interaction of IgG antibodies to effector cells to trigger inflammatory sequelae.

TL;DR: The in vivo consequences of FcγRII deficiency in the inflammatory response using a mouse model of IC alveolitis are described and contrasting roles for the cellular receptors for IgG on inflammatory cells are revealed, providing a regulatory mechanism for setting thresholds for IC sensitivity based on the ratio of ITIM to ITAM F cγR expression.

TL;DR: The diverse downstream proinflammatory, anti-inflammatory and immunomodulatory consequences of the engagement of type I and type II Fc receptors in the context of infectious, autoimmune, and neoplastic disorders are discussed.